Original language | Undefined/Unknown |
---|---|
Pages (from-to) | 1631-1639 |
Number of pages | 9 |
Journal | Annals of oncology : official journal of the European Society for Medical Oncology |
Volume | 28 |
Issue number | 7 |
DOIs | |
Publication status | Published - 2017 |
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. / Long, G.V.; Flaherty, K.T.; Stroyakovskiy, D.; Gogas, H.; Levchenko, E.; de Braud, F.; Larkin, J.; Garbe, C.; Jouary, T.; Hauschild, A.; Chiarion-Sileni, V.; Lebbe, C.; Mandalà, M.; Millward, M.; Arance, A.; Bondarenko, I.; Haanen, J.B.A.G.; Hansson, J.; Utikal, J.; Ferraresi, V.; Mohr, P.; Probachai, V.; Schadendorf, D.; Nathan, P.; Robert, C.; Ribas, A.; Davies, M.A.; Lane, S.R.; Legos, J.J.; Mookerjee, B.; Grob, J.-J.
In: Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 28, No. 7, 2017, p. 1631-1639.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
AU - Long, G.V.
AU - Flaherty, K.T.
AU - Stroyakovskiy, D.
AU - Gogas, H.
AU - Levchenko, E.
AU - de Braud, F.
AU - Larkin, J.
AU - Garbe, C.
AU - Jouary, T.
AU - Hauschild, A.
AU - Chiarion-Sileni, V.
AU - Lebbe, C.
AU - Mandalà, M.
AU - Millward, M.
AU - Arance, A.
AU - Bondarenko, I.
AU - Haanen, J.B.A.G.
AU - Hansson, J.
AU - Utikal, J.
AU - Ferraresi, V.
AU - Mohr, P.
AU - Probachai, V.
AU - Schadendorf, D.
AU - Nathan, P.
AU - Robert, C.
AU - Ribas, A.
AU - Davies, M.A.
AU - Lane, S.R.
AU - Legos, J.J.
AU - Mookerjee, B.
AU - Grob, J.-J.
N1 - cited By 15
PY - 2017
Y1 - 2017
U2 - 10.1093/annonc/mdx176
DO - 10.1093/annonc/mdx176
M3 - Articolo
VL - 28
SP - 1631
EP - 1639
JO - Annals of Oncology
JF - Annals of Oncology
SN - 0923-7534
IS - 7
ER -